Q-omics provides the consensus-scored RPL5P6 profile across patient tissues and cancer cell-line models. RPL5P6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL5P6 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, RPL5P6 RNA expression shows 6,968 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LUAD, and THYM as cancer lineages where RPL5P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P6 survival associations across molecular data types. RPL5P6 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P6 RNA expression–survival associations across cancer types. High RPL5P6 expression shows unfavorable associations in UCEC, ACC, LUAD and LUSC, but favorable associations in CESC and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL5P6 RNA expression.
This table summarizes RPL5P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P6 shows lower tumor expression in PAAD, UCEC, BRCA and KIRP and higher tumor expression in LUAD and LIHC. The LUAD box plot shows higher RPL5P6 RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p = .006).
This table shows molecular features associated with RPL5P6 in patient tissues and cancer cell lines. In patient samples, RPL5P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
